Skip to main content
OpenTrials
Completed

NCT Number: NCT04238793

Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Kolon Investigative Site : CenExel JBR

Salt Lake City, Utah, 84107, United States

About this study

This is a first-in-human (FIH), multicenter, double-blind, placebo-controlled, parallel-group, escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031 administered by transforaminal epidural injection to subjects aged 18 to 75 years with neuropathic pain due to LSR.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

To participate in the study, subjects must have met the following criteria at Visit 1 (Screening,

Day -56 to Day -15):

  • The subject signed a written informed consent for study participation including the 1-year double-blind treatment period and 1-year, open-label, long-term extension period.

Informed consent must have been obtained before any screening activities are conducted.

  • The subject, male or female, must have been between the ages of 18 and 75 years, inclusive.
  • The subject must have had a body mass index of ≤35 kg/m².
  • The subject must have had a diagnosis of pain due to LSR, with all of the following characteristics:
  • The subject perceived pain in 1 or both lower limbs at areas that are consistent with the area innervated by the lumbar 4 or 5 or sacral 1 (L4, L5, S1) nerve roots, with or without other sensory symptoms in the affected areas (typically, the pain may have been perceived in the buttock, thigh, calf, leg, foot, or toes). If both limbs were affected, pain had to be asymmetrical (ie, pain worse in 1 limb).
  • Pain in the leg radiated to below the knee.
  • Pain in the leg was worse during rest and/or at night and not solely present upon walking.
  • The history of the pain suggested that the cause of the LSR was due to the injury of the lumbosacral nerve root(s) by degenerative disease of the vertebrae in the lumbosacral spine or associated soft tissues (including the intervertebral discs).
  • The duration of the pain since onset was ≥6 months.
  • Based on clinical history, the intensity of the neuropathic (leg) pain had been stable during the 4-week period before screening (the pain may have fluctuated and may have been worse at night or at rest but was present on most days of the week).
  • Pain in the leg (worse affected leg) was worse than pain in the back.

Exclusion criteria

Subjects were excluded from the study if 1 or more of the following criteria were applicable:

  • The subject had:
  • Neuropathic pain due to causes other than that specified in the inclusion criteria (eg, postherpetic neuralgia; painful diabetic neuropathy; mononeuritis multiplex; central poststroke pain; spinal abscess, infection, hematoma, spondylolisthesis with displacement, or malignancy; phantom limb pain; peripheral neuropathy due to alcoholism, malignancy, HIV, syphilis; drug abuse; vitamin B12 deficiency; hypothyroidism; liver disease; toxic exposure).
  • Radicular pain at more than 1 spinal level, unstable spine, spondylolisthesis (>Grade 1), spondylolysis, caudal equina syndrome, arachnoiditis, progressive neurological deficit, moderate to severe central spinal canal stenosis (congenital or acquired) from other origins, vertebral compression fracture(s).
  • Pain that was associated with a substantial somatic pain component in lower limbs or other parts of the body apart from the back (eg, non-neuropathic/musculoskeletal pain) or more than 1 cause or potential cause for pain symptoms in low limbs.
  • Any painful concurrent rheumatic disease such as, but not limited to, fibromyalgia, rheumatoid arthritis, or osteoarthritis that in the investigator's opinion would have prevented the subject from reliably delineating or assessing his/her pain due to LSR. Note: Any question regarding the acceptability of the etiology of the neuropathic pain was to be discussed with the medical monitor.
  • Had lumbar stenosis with pain present solely upon walking. Presence of lumbar narrowing on MRI was acceptable if the pain was not solely present upon walking.
  • In the investigator's opinion, the subject was unable to reliably delineate or assess his/her own pain by anatomical location/distribution (eg, the subject could not reliably tell the difference between his/her back pain and lower limb pain and could not rate the intensity of each separately).
  • The subject had pain in the lower limbs solely upon walking and not at rest.

Treatment and study plan

KLS-2031

Drug

KLS-2031 administered by transforaminal epidural injection

Placebo

Other

Normal Saline (0.9%) administered by transforaminal epidural injection

Primary outcomes

  1. The safety and tolerability of KLS-2031

    Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52

    Frequency and nature of AEs, laboratory test results, vital sign measurements, physical and complete neurological examinations, and 12-lead electrocardiograms (ECGs)

Secondary outcomes

  1. Long-term safety and tolerability of KLS-2031

    Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 78, Week 104

    Frequency and nature of AEs, laboratory test results, vital sign measurements, physical and complete neurological examinations, and 12-lead ECGs

  2. Local safety and tolerability (including AEs, clinical laboratory parameters, and physical examination) of administration by transforaminal epidural injectionepidural injection as measured by the occurrence of injection site reactions

    Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52

    The occurrence of injection site reactions

  3. Change from baseline in weekly mean of the average daily pain score

    Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104

    calculated as the average of the subject's last 4 available PI-NRS daily scores in the week before the study visit

  4. Change from baseline in Galer Neuropathic Pain Scale (Galer NPS)

    Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104

  5. Number and percentage of subjects who have ≥30% and ≥50% reduction from baseline in the average daily pain score (PI-NRS)

    Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104

  6. Time (number of weeks) to ≥30% and ≥ 50% reduction from baseline in the average daily pain score (PI-NRS)

    Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104

  7. Number and percentage of subjects who are much improved or very much improved from baseline

    Time frame: Week 12, Week 26, Week 52, Week 104

    based on the Patient Global Impression of Change (PGIC)

  8. Change from baseline in the modified Modified Roland-Morris Disability Questionnaire (RMDQ) scores (back pain and leg pain)

    Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104

  9. Amount of rescue medication used (in terms of dosage/day)

    Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52

  10. Time to treatment failure

    Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52

    , defined as the day and time a subject starts pain medication other than acetaminophen for the treatment of neuropathic pain

  11. Change from baseline in the Simple Profile of Moods States (POMS) - 2 Short Form total score and domain scores

    Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104

  12. Change from baseline in Daily Sleep Interference Scale (DSIS) score

    Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104

  13. Change from baseline in the Short Form-36 v2 (SF-36v2) score

    Time frame: Week 12, Week 26, Week 52, Week 104

  14. Assessment of suicidality

    Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52

    using the Columbia Suicide Severity Rating Scale (C-SSRS)

Sponsors and collaborators

Lead sponsor

Kolon Life Science

Industry

Registry information

Official study title

A Phase 1/2a, First-in-Human, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Therapeutic Activity of Single Ascending Doses of KLS-2031 Administered by Transforaminal Epidural Injection in Patients With Neuropathic Pain From Lumbosacral Radiculopathy

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Jan 23, 2020
Registry last updated
Jul 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.